The SPORE Tissue Procurement and Analysis Facility (TPA) provides centralized, quality controlled, quality assured procurement, processing, analysis, storage and distribution of normal and malignant breast tissue from UNC Hospitals. Whenever possible, corresponding serum and plasma are also obtained. All procured specimens are reviewed by the Facility Pathologist to ensure that representative tissue is banked and distributed. Our tissue procurement activities have expanded to include Rex Hospital, a large Hospital in Raleigh, N.C., new to the UNC Health Care System, dramatically increasing our access to breast specimens. The TPA facility procures and distributes human specimens from patients who have consented to having their specimens used in basic, translational, population and clinical cancer research. The facility also provides analysis services, including tissue sectioning for frozen and paraffin embedded specimens, preparation of tissue microarrays (TMAs), immunohistochemistry and fluorescence in situ assays, technology development and access to state-of-the-art tissue-based technology, including automated equipment and laser-capture microdissection. Expert personnel provide consultation and training to faculty and staff in these applications. The facility also serves as a central clearing house for the Carolina Breast Cancer Study - banking anddistributing unstained sections for multiple assays andcentralized repository for the InterSPORE ISPY trial (Intergroup Neoadjuvant study: SPORE/CALGB/ ACRIN). Customized databases serve to monitor and survey all specimens and associated data, providing a coordinated system of quality control, sample tracking and distribution of specimens to appropriate investigators. The TPA has implemented policies and procedures to support these services and address technical, medical and legal issues, as well as protection of patient privacy and confidentiality. These policies developed in collaboration with pathology, surgery, the clinical protocol office and integrated with clinical and basic research policies allow a uniform, streamlined coordinated process of tissue procurement, handling, process, triage and analysis. The facility meets with each investigator to customize needs. The productivity and services provided by the TPA continues, as evidenced by numerous publications from user investigators and continued support of each of the SPORE projects and developmental studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-15
Application #
7558851
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
15
Fiscal Year
2007
Total Cost
$194,329
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386

Showing the most recent 10 out of 598 publications